Antitumor activity of LSD1 inhibitors in SCLC is also attributed to induction of NOTCH1 expression and subsequent activation of NOTCH signaling, which contributes to strong ASCL1 down-regulation and repression of NE genes (Fig. 5) (116). The gene discussed is ASCL1; the disease is small cell lung carcinoma.